Menadione sodium bisulfite
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Others |
| Catalog number | BBF-03817 |
| CAS | 130-37-0 |
| Molecular Weight | 276.24 |
| Molecular Formula | C11H9NaO5S |
| Purity | >95% |
Online Inquiry
Description
Menadione sodium bisulfite is a water-soluble form of menadione, which belongs to the Vitamin K class of compounds. It is a possible anticancer agent able to induce apoptosis. It can be used for bleeding caused by vitamin K deficiency.
Specification
| Synonyms | Sodium menadione bisulfite; Dohyfral; Hemoklot |
| Storage | Store at -20°C |
| IUPAC Name | sodium;2-methyl-1,4-dioxo-3H-naphthalene-2-sulfonate |
| Canonical SMILES | CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+] |
| InChI | InChI=1S/C11H10O5S.Na/c1-11(17(14,15)16)6-9(12)7-4-2-3-5-8(7)10(11)13;/h2-5H,6H2,1H3,(H,14,15,16);/q;+1/p-1 |
| InChI Key | XDPFHGWVCTXHDX-UHFFFAOYSA-M |
Properties
| Melting Point | 121-124°C |
Reference Reading
1.The SmeYZ efflux pump of Stenotrophomonas maltophilia contributes to drug resistance, virulence-related characteristics, and virulence in mice.
Lin YT1, Huang YW2, Chen SJ3, Chang CW2, Yang TC4. Antimicrob Agents Chemother. 2015 Jul;59(7):4067-73. doi: 10.1128/AAC.00372-15. Epub 2015 Apr 27.
The resistance-nodulation-division (RND)-type efflux pump is one of the causes of the multidrug resistance of Stenotrophomonas maltophilia. The roles of the RND-type efflux pump in physiological functions and virulence, in addition to antibiotic extrusion, have attracted much attention. In this study, the contributions of the constitutively expressed SmeYZ efflux pump to drug resistance, virulence-related characteristics, and virulence were evaluated. S. maltophilia KJ is a clinical isolate of multidrug resistance. The smeYZ isogenic deletion mutant, KJΔYZ, was constructed by a gene replacement strategy. The antimicrobial susceptibility, virulence-related physiological characteristics, susceptibility to human serum and neutrophils, and in vivo virulence between KJ and KJΔYZ were comparatively assessed. The SmeYZ efflux pump contributed resistance to aminoglycosides and trimethoprim-sulfamethoxazole. Inactivation of smeYZ resulted in attenuation of oxidative stress susceptibility, swimming, flagella formation, biofilm formation, and secreted protease activity.
2.Cytoprotective Effect of Afobazole and Its Main Metabolite M-11.
Kadnikov IA1, Voronin MV, Seredenin SB. Bull Exp Biol Med. 2015 May;159(1):44-7. doi: 10.1007/s10517-015-2886-9. Epub 2015 Jun 2.
Cell damage depending on activity of quinone reductase 2 (MT3 receptor) was simulated in experiments on bone marrow cell suspension and assessed by menadione-induced DNA breaks measured by comet assay. We analyzed the protective effect of afobazole interacting with MT1, MT3, σ1 receptors, and monoamine oxidase A and its main metabolite M11 that specifi cally binds to MT3 receptors. Both compounds reduced the level of menadione-induced DNA damage (afobazole was effective in lower concentrations in comparison with M-11). Conclusion was made on the contribution of MT3 receptors to the protective effect of afobazole, but the observed concentration differences indicate possible contribution of other targets of anxiolytic drug to the protective mechanisms.
3.Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.
Barton CA1, Johnson NB2, Case J3, Warden B4, Hughes D5, Zimmerman J6, Roberti G7, McMillian WD8, Schreiber M9. Am J Emerg Med. 2015 Nov;33(11):1562-6. doi: 10.1016/j.ajem.2015.06.010. Epub 2015 Jun 12.
Bleeding events and life-threatening hemorrhage are the most feared complications of warfarin therapy. Prompt anticoagulant reversal aimed at replacement of vitamin K-dependent clotting factors is essential to promote hemostasis. A retrospective cohort study of warfarin-treated patients experiencing a life-threatening hemorrhage treated with an institution-specific warfarin reversal protocol (postimplementation group) and those who received the prior standard of care (preimplementation group) was performed. The reversal protocol included vitamin K, 3-factor prothrombin complex concentrate, and recombinant factor VIIa. Demographic and clinical information, anticoagulant reversal information, and all adverse events attributed to warfarin reversal were recorded. A total of 227 patients were included in final analysis, 109 in the preimplementation group and 118 in the postimplementation group. Baseline patient characteristics were similar in both groups, with the exception of higher average Sequential Organ Failure Assessment scores in the postimplementation group (P = .
Recommended Products
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
